Pamela Guerrerio, MD, PhD | American Lung Association

Pamela Guerrerio, MD, PhD

Research Awards Nationwide Recipient (2014-2016)

Johns Hopkins University, Baltimore, MD
Development of a Novel Treatment for Asthma

While current asthma therapies improve control of symptoms in many patients, there is little evidence that these treatments prevent or reverse the remodeling of the airways that results from repeated inflammation and injury. Airway remodeling leads to irreversible airway obstruction and worsening lung function in asthmatic children as young as 4 years old. Strong evidence suggests that airway remodeling results from overexpression of the molecule “transforming growth factor beta” (TGFbeta). Losartan, an FDA-approved drug that’s been safely used for years to treat patients with hypertension, has been found to down regulate TGFbeta signaling and is remarkably effective in treating conditions caused by excessive TGFbeta signaling. Dr. Guerrerio will test whether losartan can reduce TGFbeta signaling in the lungs of mice with asthma, and thereby improve lung function, reduce airway inflammation, and prevent and/or reverse airway remodeling. If this approach proves to be successful in mice, then human trials of losartan to treat asthma could follow quickly.

Ask An Expert

Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

Get help
We need your generous support

Make a difference by delivering research, education and advocacy to those impacted by lung disease.

What is LUNG FORCE?

LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

Get involved
Join the fight for healthy lungs and healthy air.
Donate Now.